CHS Pharma Inc.
11Patents
11Active
11Granted
46Portfolio score
Filing activity: Oct 26, 2007 → Jan 14, 2021 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8487128B2 | Protection of normal cells | Emerging Cross-Sectional Technologies | 31 | Active |
| US9827220B2 | Treatment for ischemic stroke | Human Necessities | 3 | Active |
| US10272063B2 | Treatment for ischemic stroke | Human Necessities | 2 | Active |
| US9050305B2 | Treatment for ischemic stroke | Human Necessities | 1 | Active |
| US8603985B2 | Treatment or prevention of cancer and precancerous disorders | Human Necessities | 1 | Active |
| US8871971B2 | Protection of normal cells | Emerging Cross-Sectional Technologies | 1 | Active |
| US12246074B2 | Granulocyte colony-stimulating factor (GCSF) gene therapy for treating neurological diseases | Chemistry; Metallurgy | 0 | Active |
| US8765808B2 | Treatment or prevention of cancer and precancerous disorders | Human Necessities | 0 | Active |
| US10945986B2 | Treatment for ischemic stroke | Human Necessities | 0 | Active |
| US10792260B2 | Retinopathy treatment | Human Necessities | 0 | Active |
| US11576945B2 | Treatment for ischemic stroke | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.